Bibliographic Details
| Title: |
The administration of interferon-beta1b and favipiravir in patients with COVID-19 pneumonia |
| Authors: |
Mehrdad Hasibi, Ali Asadollahi-Amin, Nozhat Besharati, Farahnaz Salehinia, Maryam Khoshnevis, Saiedeh Ahmadi, Sima Maziar, Goli Siri, Maryam Moosivand Darani, Maryam Taghizadeh |
| Source: |
Trends in Pharmaceutical Sciences, Vol 7, Iss 2, Pp 127-134 (2021) |
| Publisher Information: |
Shiraz University of Medical Sciences, 2021. |
| Publication Year: |
2021 |
| Collection: |
LCC:Pharmacy and materia medica |
| Subject Terms: |
covid-19 pneumonia, interferon-beta1b, favipiravir, treatment, Pharmacy and materia medica, RS1-441 |
| More Details: |
Purpose: To assess the efficacy of interferon-beta1b (INF-beta1b) in combination with favipiravir in early treatment of patients with COVD-19 pneumonia. Methods: This prospective non-controlled study was performed on admitted patients with moderate to severe COVID-19 disease to Amir-Alam hospital. The diagnosis of COVID-19 pneumonia was based on positive RT-PCR test from nasopharyngeal samples and typical spiral chest CT scan findings. At the time of this study, there was the shortage of efficient anti-COVID drugs especially “Remdesivir” due to sanction of Iran. All the patients received subcutaneous IFN-beta1b plus favipiravir. The patients with severe infection received intravenous dexamethasone. Those who underwent invasive or noninvasive mechanical ventilation, at the admission onset, were excluded from the study. Results: One hundred and eighty-two patients with moderate to severe COVID-19 pneumonia were included in this study. Among182 patients, 90 cases had moderate and 92 had severe pneumonia. Twenty-one cases with severe pneumonia and 14 cases with moderate pneumonia were transferred to ICU to receive invasive or non-invasive mechanical ventilation. The mean duration of hospital ward admission and ICU stay was 10.69±7.54 and 5.45±2.72 days, respectively. One hundred and seventy-four patients (80.7 %) recovered completely and discharged without need to ICU admission. The response rate was the same in patients with moderate and severe pneumonia. Nine cases (4.9 %) were passed away. Diabetic patients had higher mortality rates. Conclusion: This study showed the efficacy of IFN-beta1b plus favipiravir in early treatment of patients with moderate to severe COVID-19 pneumonia who did not need to mechanical ventilation. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
2423-5652 |
| Relation: |
https://tips.sums.ac.ir/article_47572_af5ff5f6d2f9a61a9fb1943731297d9f.pdf; https://doaj.org/toc/2423-5652 |
| DOI: |
10.30476/tips.2021.90503.1086 |
| Access URL: |
https://doaj.org/article/d3b9713b46e14ef7a38ef0314fc13015 |
| Accession Number: |
edsdoj.3b9713b46e14ef7a38ef0314fc13015 |
| Database: |
Directory of Open Access Journals |
